Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
The latest update is out from Modalis Therapeutics Corporation ( (JP:4883) ).
JCR Pharmaceuticals and Modalis Therapeutics have advanced to the next phase of their joint research agreement, focusing on developing a novel gene therapy for a central nervous system disease. This collaboration combines JCR’s J-Brain Cargo technology and Modalis’ CRISPR-GNDM platform, aiming to improve the efficacy and safety of treatments through innovative drug delivery methods, though the financial impact on both companies is expected to be minor this fiscal year.
More about Modalis Therapeutics Corporation
JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceuticals company focused on treatments for rare and genetic diseases, including conditions like growth disorder and Fabry disease. Modalis Therapeutics Corporation, founded in 2016, specializes in epigenetic medicine and develops therapeutics for genetic disorders, utilizing their proprietary CRISPR-GNDM technology.
YTD Price Performance: 0%
Average Trading Volume: 15,110,181
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen7.08B
For detailed information about 4883 stock, go to TipRanks’ Stock Analysis page.